Blog

SSDP's partnership with Overdrive Defense gets mention in The New York Times. Read the article here ...

Vibe Science hosts Ryan Alford and Chris Hansen bring listeners on a journey through the evolving world of drug policy. Thank you for inviting SSDP's Kat Murti and Gina Giorgio onto the podcast to discuss psychedelics, drug policy, and the science of healing. Watch the episode here ...

Thank you for the Boston University News Service for their article discussing Question 4 on the Massachusetts ballot. Read the article here. “Typically, the way we approach mental healthcare is through a long path of seeing a therapist for potentially years,” said Gina Giorgio, Director of Strategy for Students for ...

Thanks to The Lutrinae, the student-run newspaper covering California State University, Monterey Bay, for posting their article, "Six tips from the Students for Sensible Drug Policy to stay safe during Halloween." "While college students may be past their candy-collecting days, unfamiliar substances, chaotic environments and inexperience mean #Halloween can still ...

We are thankful to NASA's Land-Cover and Land-Use Change (LCLUC) Program for mentioning SSDP on their podcast. Listen to the podcast here ...

Community matters at SSDP, and that is why we are hosting monthly "SSDP Hangouts" for the SSDP family to get together to share upcoming projects, seek advice, and meet like-minded leaders. What to expect at a SSDP virtual hangout: Share upcoming thoughts about the upcoming election Learn about projects led ...

Thank you to Lucid News for sharing information about the importance of Question 4 on the ballot in Massachusetts. SSDP's Campaign Educators have been all over the state urging the community to register to vote, and sharing important info on what this measure means for psychedelic policy in the state ...

Local advocacy groups including SSDP will host an informal reception at the Garden Cinemas on Sunday, Nov. 3, at 4:30 p.m., to discuss Yes on 4 followed by a screening of the feature-length documentary “Music for Mushrooms.” Thanks to the Recorder for mentioning SSDP in the Weekly Recorder. Read more ...

We are impressed by our Board Member, Axel Bilbao, for his honest and authentic sharing of his personal journey on the Church & Other Drugs podcast. Tune into Episode 1 of Axel's featured podcast appearances here ...

FOR IMMEDIATE RELEASE: SSDP Science Policy Committee successfully pushes back on DEA effort to criminalize psychedelic research On Friday August 26, 2022, the Drug Enforcement Administration (DEA) withdrew proposed Schedule I status for 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). The notice states that “The Drug Enforcement Administration (DEA) is withdrawing a ...

Two years ago today, SSDP and Last Prisoner Project joined forces to mobilize a rally in Washington D.C. for cannabis justice. Our goal then (and now) is to keep reminding the President of his campaign promise to release cannabis prisoners and provide them with retroactive relief. While this administration has ...

We are grateful to Psychedelics Today for educating the community about the importance of DOI & DOC. “I have many colleagues who work with these compounds who will testify in the upcoming hearing, and that is only a subset of the research community,” said Elijah Ullman, Chair of SSDP's Science ...

In a significant development for psychedelics research, a Drug Enforcement Administration (DEA) administrative law judge has rejected the agency's request to block key witnesses and evidence in an upcoming hearing. The case, set for November, challenges the DEA's proposed ban on two psychedelic compounds, DOI and DOC, which are used in research. Thank you to Benzinga ...

SSDP is proud to serve as a community partner for MAPS Psychedelic Science, taking place June 16-20, 2025 at the Colorado Convention Center in Denver. In 2023, Psychedelic Science hosted over 12,000 guests and was the largest psychedelic gathering in the world with classes and workshops, 10 educational stages, expo ...

“Science prevails!” SSDP Executive Director Kat Murti told Marijuana Moment on Monday. “The DEA is trying to force medical research into the dark ages by criminalizing DOI and DOC—essential research chemicals in pre-clinical psychiatry and neurobiology whose status as unscheduled compounds has made them de facto tools for researchers studying ...

SSDP University of Alabama Chapter was featured in the Crimson White for holding a "Spooktacular Substance Smarts" event to raise awareness about potentially harmful Halloween-related substance myths. Marlie Thomson, a senior majoring in interdisciplinary studies with an in-depth study in sociology and social justice, founded UA SSDP in 2022 aiming ...

We all know that words matter, but can the way we speak about a plant have legal implications? SSDP appointed board member and Prop 19 alum Evan Nison believes so, and broaches this important topic in a recent article he wrote that was published in Legal Reader. The article reflects ...

Yes on 4, The Natural Psychedelic Substances Act, is a citizen-led ballot question that will enable therapeutic access to natural psychedelic medicines that show promise in treating mental health conditions in Massachusetts. The measure creates a regulated framework for supervised use with trained facilitators at licensed psychedelic therapy centers and ...

SSDP is leading the fight to keep psychedelic research legal! The DEA wants to add two important research chemicals—2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)—to Schedule I of the Controlled Substances Act, despite decades of safe usage in labs and no history of abuse. DOI and DOC’s current status as unscheduled compounds ...

Published on October 7, 2024 in Investors Hangout by Owen Jenkins. The Drug Enforcement Administration (DEA) has caused quite a stir by denying testimony from important witnesses just before scheduled hearings on the potential classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). This decision has led to significant backlash ...